Plant Comparison

Horse Chestnut vs Japanese knotweed

A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.

First plant
Second plant
Show:
Plant AHorse ChestnutAesculus hippocastanumSapindaceaeFull monograph →
Plant BJapanese knotweedReynoutria japonicaPolygonaceaeFull monograph →

At a glance

Horse Chestnut and Japanese knotweed: they share 4 indicated uses (arthritis / joint pain, cancer (anticancer research), inflammation (general), …); 2 pharmacological actions in common.

Horse ChestnutJapanese knotweed
Constituents24
Pharmacological actions43
Indicated uses85
Safety notes22
Cited sources1914
Indicated uses
Only Horse Chestnut
HaemorrhoidsPain (general)Swelling / fluid retentionVaricose veins
Shared (4)
Arthritis / joint painCancer (anticancer research)Inflammation (general)Skin irritation
Only Japanese knotweed
Cardiovascular / heart health
Pharmacological actions
Only Horse Chestnut
Anti-oedematous (reduces swelling)Venotonic / vasoprotective
Shared (2)
Anti-inflammatoryAnticancer (preclinical)
Only Japanese knotweed
Antioxidant

Evidence face-off — shared uses

ConditionHorse ChestnutJapanese knotweedVerdict
Arthritis / joint pain2/102/10Comparable evidence
Cancer (anticancer research)2/102/10Comparable evidence
Inflammation (general)2/107/10Stronger for Japanese knotweed
Skin irritation2/101/10Comparable evidence

Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.

Key Constituents

Triterpene saponins (escin / aescin)[1, 6, 7, 8, 9]

The active mixture responsible for the venotonic and anti-oedematous effects; extracts are standardised to it. Escin is available as oral drages and a transdermal gel, with efficacy shown in chronic venous insufficiency and blunt-trauma injury.

Triterpene saponinsTerpenes / terpenoidsSaponinsEscin (aescin)
Flavonoids and coumarins (aesculin)[5, 6]

Supporting constituents of the seed.

FlavonoidsCoumarins
Stilbenes (resveratrol, piceid)[1, 6]

Considered the principal bioactive constituents, responsible for much of the antioxidant, anti-inflammatory and cardioprotective activity attributed to this root.

Anthraquinones (emodin, physcion)[1]

Emodin has laxative and anti-inflammatory activity at typical concentrations but can cause gastrointestinal upset at high doses.

Anthraquinones
Polysaccharides[5]

Studied for immunomodulatory and other bioactivities.

Polysaccharides
Phenolic glycosides[8]

Minor phenolic constituents of the rhizome.

GlycosidesPhenolic compounds

Pharmacological Actions

Anti-inflammatory[1, 2, 4, 8]

Anti-oedematous and anti-inflammatory - escin reduces vascular permeability in inflamed tissue and exerts venotonic effects on veins

Anti-oedematous (reduces swelling)[8]

Anti-oedematous and anti-inflammatory - escin reduces vascular permeability in inflamed tissue and exerts venotonic effects on veins

Anticancer (preclinical)[6, 11, 12, 13, 14, 15]

Escin, the triterpene saponin of Aesculus hippocastanum, induces apoptosis and cell-cycle arrest and chemosensitizes breast, hepatocellular, lung and pancreatic cancer cells (preclinical, including in vivo xenograft models).

Venotonic / vasoprotective[1, 8]

Anti-oedematous and anti-inflammatory - escin reduces vascular permeability in inflamed tissue and exerts venotonic effects on veins; Relief of haemorrhoid symptoms (venotonic)

Anti-inflammatory[1, 2, 3, 5, 6, 9, 11, 12, 13]
Anticancer (preclinical)[1, 3, 6, 7, 11, 12, 13]
Antioxidant[1, 3, 5, 6, 11, 12, 13]

Traditional & Indicated Uses

Arthritis / joint pain[4, 6, 8, 11, 16]Traditional · 2/10

inferred from anti-inflammatory action

Evidence: 2
Label: Arthritis / joint pain
Cancer (anticancer research)[6, 11, 12, 13, 14, 15]Traditional · 2/10

Escin shows antiproliferative and pro-apoptotic activity and enhances chemotherapy/immunotherapy efficacy in breast (MCF-7), hepatocellular, lung and pancreatic cancer models; it modulates NF-kappaB, p53, p38 MAPK/ERK and PD-L1 (preclinical).

Evidence: 2
Label: Cancer (anticancer research)
Haemorrhoids[8]Traditional · 2/10

Relief of haemorrhoid symptoms (venotonic)

Evidence: 2
Label: Haemorrhoids
Inflammation (general)[6, 8, 11, 16]Traditional · 2/10

inferred from anti-inflammatory action

Evidence: 2
Label: Inflammation (general)
Pain (general)[7, 17, 18]Good · 7/10

Chronic venous insufficiency - reduces leg pain, swelling (oedema), heaviness and itching; supports varicose veins

Evidence: 7
Label: Pain (general)
Skin irritation[8]Traditional · 2/10

inferred from anti-inflammatory action

Evidence: 2
Label: Skin irritation
Swelling / fluid retention[7, 17, 18]Good · 7/10

Chronic venous insufficiency - reduces leg pain, swelling (oedema), heaviness and itching; supports varicose veins

Evidence: 7
Label: Swelling / fluid retention
Varicose veins[5, 7, 17, 18]Good · 7/10

Chronic venous insufficiency - reduces leg pain, swelling (oedema), heaviness and itching; supports varicose veins

Evidence: 7
Label: Varicose veins
Arthritis / joint pain[9, 11, 12, 13]Traditional · 2/10

inferred from anti-inflammatory action

Evidence: 2
Label: Arthritis / joint pain
Cancer (anticancer research)[7]Traditional · 2/10

inferred from anticancer action

Evidence: 2
Label: Cancer (anticancer research)
Cardiovascular / heart health[6, 11, 12, 13]Traditional · 1/10
Evidence: 1
Label: Cardiovascular / heart health
Inflammation (general)[2, 11, 12, 13]Good · 7/10

inferred from anti-inflammatory action

Evidence: 7
Label: Inflammation (general)
Skin irritation[11, 12, 13]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Skin irritation

Safety, Cautions & Contraindications

Safety note[7]Info

Use only standardised, processed seed extract. Raw conkers, leaves and bark contain toxic esculin and can cause poisoning - never eat raw horse chestnut.

Safety note[7]Caution

May increase bleeding risk, so use caution with anticoagulant/antiplatelet medicines; use caution in kidney disease and avoid in pregnancy and breastfeeding.

Safety note[11, 12, 13]Caution

Japanese knotweed root contains resveratrol and emodin; high doses of emodin may cause GI discomfort and have laxative effects. Not recommended during pregnancy (emodin has potential teratogenic effects in animal studies). May interact with anticoagulants and antiplatelet medications. Quality control of commercial preparations is important as invasive weed extracts vary significantly.

Safety note[11, 12, 13, 14]Info

Duke (2002) rates Japanese knotweed (listed as Hu-Zhang, Fallopia japonica) as +++ and highlights its rich content of resveratrol and emodin. Experimental evidence (score 1) supports COX-2 inhibitory, antioxidant, anti-inflammatory, hepatoprotective, and lipid-lowering activities — largely attributed to resveratrol. Duke notes its use in traditional Chinese medicine for fractures, burns, abscesses, and gynecological conditions. No significant clinical trials were available at time of publication, but resveratrol's biological activity is well-documented in vitro (Duke, 2002).

External Ids

Gbif: 3189815
Wikidata: Q26899
Gbif: 2889173
Wikidata: Q18421053

Botanical Description

Large deciduous tree, to 25-30 m, with a broad domed crown and stout, upward-arching branches. The leaves are opposite and palmately compound, with five to seven large, obovate, toothed leaflets radiating from a long stalk. In spring the tree bears large, showy, upright pyramidal flower spikes ('candles') of white flowers marked with yellow or pink at the base. The glossy brown seeds ('conkers') develop inside a spiky green husk and fall in autumn.[1]

Height: Up to 25-30 m
Habit: Large deciduous tree
Leaves: Opposite, palmately compound with 5-7 large obovate toothed leaflets
Flowers: Showy, upright, pyramidal spikes ('candles') of white flowers marked yellow/pink at the base
Stem: Stout trunk with a broad domed crown of upward-arching branches
Root: Not medicinally used
Fruit: Glossy brown seed ('conker') enclosed in a spiny green husk
Flowering Period: April-May

Vigorous, invasive rhizomatous perennial (Polygonaceae) with hollow, bamboo-like, jointed stems 1-3 m tall (occasionally taller), speckled reddish-purple. Leaves are broad, heart- to shovel-shaped with a flat base. Abundant sprays of small, creamy-white flowers appear in late summer, followed by small winged fruit.[6]

Height: 1-3 m (occasionally to 4 m+)
Habit: Vigorous, invasive, rhizomatous perennial
Leaves: Broad, heart- to shovel-shaped, flat-based
Flowers: Small, creamy-white, in abundant sprays
Stem: Hollow, bamboo-like, jointed, reddish-purple speckled
Root: Extensive, deep, aggressively spreading rhizome
Fruit: Small winged achenes
Flowering Period: August-October

Habitat

Native to the Balkan Peninsula, and widely planted and naturalised as an ornamental and avenue tree across temperate Europe, North America and elsewhere.[1]

Native to East Asia (Japan, China, Korea), now a notorious invasive species across Europe and North America, growing in disturbed ground, riverbanks, roadsides and waste land, spreading aggressively via an extensive rhizome network.[6]

Harvesting

The seeds are gathered as they fall from the spiny husks in autumn; medicinal use requires a standardised, processed extract, since the raw seed, bark and leaves contain toxic esculin and must never be eaten raw.[1, 7]

Parts: Seed (standardised extract)
Season: Autumn

The rhizome/root, the main medicinal part, is dug in autumn or winter when resveratrol content is highest; young spring shoots (stems) are also edible and used. Strict containment is required when harvesting, given the plant's severe invasiveness.[6]

Parts: Root, Stem
Season: Root in autumn/winter; young stems in spring

Traditional Uses

Horse chestnut seed has a long folk history as a remedy for varicose veins, haemorrhoids and 'heavy legs', and was also used topically for rheumatic pain and bruising. Modern use is almost exclusively as a standardised seed extract for chronic venous insufficiency, confirming this traditional venous-support reputation.[1]

Known as Hu Zhang in Traditional Chinese Medicine, Japanese knotweed root has a centuries-old use for inflammation, infections, jaundice and menstrual complaints. Modern interest centres on its resveratrol and emodin content, now studied (as Polygonum cuspidatum extract) for antioxidant, anti-inflammatory, cardioprotective and hepatoprotective activity, and more recently for supportive use in acute respiratory infections.[2, 3, 6]

Preparations

Standardised extract (oral)[1, 8]

Standardised seed extract, normalised to escin content, taken as tablets or capsules for chronic venous insufficiency; this is the best-studied clinical form.

Topical gel[8]

Escin-containing transdermal gel applied to the skin over affected veins or bruised tissue.

Decoction[6]

Dried rhizome simmered in water, the classic Traditional Chinese Medicine preparation.

Standardised resveratrol extract (capsule)[1]

The modern commercial supplement form, standardised for resveratrol content.

Dosage

Standardised oral extract[8]

Clinical studies commonly use extracts standardised to around 100-150 mg escin daily, in divided doses. Educational reference only, not a prescription.

Topical gel[10]

The EU herbal monograph gives semi-solid dosage forms containing the equivalent of 0.4% triterpene glycosides calculated as protoaescigenin (or, depending on the preparation, 0.85-20% herbal preparation), applied as a thin layer to the affected area 1-3 times daily, in adults and elderly. Educational reference only, not a prescription.

Standardised extract[11, 12, 13]

Duke (2002) and general phytotherapy guidance treat this as an experimentally supported herb without a single agreed clinical dose; commercial resveratrol-standardised extracts should be dosed per product labelling. Educational reference only, not a prescription; avoid in pregnancy.

References

REF-2402, REF-2403, REF-2404, REF-2405, REF-2406
REF-0979, REF-0980, REF-0981, REF-0982, REF-0983, REF-0984, REF-0985, REF-0986, REF-0987, REF-0988

Drug Class Interactions

Safety note[19]Caution
Drug Class: anticoagulants-antiplatelets
Mechanism: Horse chestnut seed contains aescin and coumarin-like constituents (esculin) that may add to the effect of blood-thinning or antiplatelet drugs, so combined use should be monitored.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

Not documented

Lookalikes Review

Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07
Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07

References & Sources

  1. Idris, S. and Mishra, A. and Khushtar, M (2020) 'Phytochemical, ethnomedicinal and pharmacological applications of escin from Aesculus hippocastanum L. towards future medicine', Journal of Basic and Clinical Physiology and Pharmacology, 31(5). doi:10.1515/jbcpp-2019-0115 Meta-analysis / review
    https://doi.org/10.1515/jbcpp-2019-0115
  2. Penaranda Figueredo, F.A. and Vicente, J. and Barquero, A.A. and Bueno, C.A (2024) 'Aesculus hippocastanum extract and the main bioactive constituent beta-escin as antivirals agents against coronaviruses, including SARS-CoV-2', Scientific Reports, 14(1), pp. 6418. doi:10.1038/s41598-024-56759-y Preclinical
    https://doi.org/10.1038/s41598-024-56759-y
  3. Idris, S. and Mishra, A. and Khushtar, M (2023) 'Phytochemical Estimation and Therapeutic Amelioration of Aesculus hippocastanum L. Seeds Ethanolic Extract in Gastric Ulcer in Rats Possibly by Inhibiting Prostaglandin Synthesis', Chinese Journal of Integrative Medicine, 29(9), pp. 818-824. doi:10.1007/s11655-023-3734-9 Preclinical
    https://doi.org/10.1007/s11655-023-3734-9
  4. Quarta, S. and Santarpino, G. and Carluccio, M.A. and Calabriso, N. and Scoditti, E. and Siculella, L. and Damiano, F. and Maffia, M. and Verri, T. and De Caterina, R. and Massaro, M (2022) 'Analysis of the Anti-Inflammatory and Anti-Osteoarthritic Potential of Flonat Fast, a Combination of Plant Extracts, Bromelain and Escin (Aesculus hippocastanum), Evaluated in In Vitro Models of Inflammation Relevant to Osteoarthritis', Pharmaceuticals, 15(10), pp. 1263. doi:10.3390/ph15101263 Preclinical
    https://doi.org/10.3390/ph15101263
  5. Owczarek, A. and Kolodziejczyk-Czepas, J. and Wozniak-Serwata, J. and Magiera, A. and Kobiela, N. and Wasowicz, K. and Olszewska, M.A (2021) 'Potential Activity Mechanisms of Aesculus hippocastanum Bark: Antioxidant Effects in Chemical and Biological In Vitro Models', Antioxidants, 10(7), pp. 995. doi:10.3390/antiox10070995 Preclinical
    https://doi.org/10.3390/antiox10070995
  6. Cheong, D.H.J., Arfuso, F., Sethi, G., Wang, L., Hui, K.M., Kumar, A.P. and Tran, T (2018) 'Molecular targets and anti-cancer potential of escin', Cancer Letters. doi:10.1016/j.canlet.2018.02.027 Preclinical
    https://doi.org/10.1016/j.canlet.2018.02.027
  7. Pittler, M.H. and Ernst, E (2012) 'Horse chestnut seed extract for chronic venous insufficiency', Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD003230.pub4 Meta-analysis / review
    https://doi.org/10.1002/14651858.CD003230.pub4
  8. Gallelli, L (2019) 'Escin: a review of its anti-edematous, anti-inflammatory, and venotonic properties', Drug Design, Development and Therapy, pp. 3425--3437. doi:10.2147/DDDT.S207720 Preclinical
    https://doi.org/10.2147/DDDT.S207720
  9. Wu, X.J., Zhang, M.L., Cui, X.Y., Gao, F., He, Q., Li, X.J., Zhang, J.W., Fawcett, J.P. and Gu, J.K (2011) 'Comparative pharmacokinetics and bioavailability of escin Ia and isoescin Ia after administration of escin and of pure escin Ia and isoescin Ia in rat', Journal of Ethnopharmacology, 139(1), pp. 201--206. doi:10.1016/j.jep.2011.11.003 Preclinical
    https://doi.org/10.1016/j.jep.2011.11.003
  10. European Medicines Agency (HMPC) (2023) 'European Union herbal monograph on Aesculus hippocastanum L., semen, Revision 1'. Available at: https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-aesculus-hippocastanum-l-semen-final-revision-1_en.pdf Traditional / reference
    https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-aesculus-hippocastanum-l-semen-final-revision-1_en.pdf
  11. Cheong, D.H.J., Arfuso, F., Sethi, G., Wang, L., Hui, K.M., Kumar, A.P. and Tran, T (2018) 'Molecular targets and anti-cancer potential of escin', Cancer Letters, pp. 1--8. doi:10.1016/j.canlet.2018.02.027 Preclinical
    https://doi.org/10.1016/j.canlet.2018.02.027
  12. Mazrouei, R. and Raeisi, E. and Lemoigne, Y. and Heidarian, E (2019) 'Activation of p53 Gene Expression and Synergistic Antiproliferative Effects of 5-Fluorouracil and beta-escin on MCF7 Cells', Journal of Medical Signals and Sensors, 9(3), pp. 196-203. doi:10.4103/jmss.JMSS_44_18 Preclinical
    https://doi.org/10.4103/jmss.JMSS_44_18
  13. Yuan, Y. and Wang, P. and Chen, S. and Cao, Z. and Ojha, S.C. and Sun, C. and Wang, G. and Wang, Z. and Gu, J. and Kang, J. and Xue, X (2025) 'Escin inhibits PD-L1 expression by suppressing the p38 MAPK/ERK signalling pathways and synergistically enhances PD-1 inhibitor efficacy in hepatocellular carcinoma', Phytomedicine, 149, pp. 157532. doi:10.1016/j.phymed.2025.157532 Preclinical
    https://doi.org/10.1016/j.phymed.2025.157532
  14. Hussain, Y. and Singh, J. and Meena, A. and Sinha, R.A. and Luqman, S (2023) 'Escin enhanced the efficacy of sorafenib by autophagy-mediated apoptosis in lung cancer cells', Phytotherapy Research, 37(10), pp. 4819-4837. doi:10.1002/ptr.7948 Preclinical
    https://doi.org/10.1002/ptr.7948
  15. Rimmon, A. and Vexler, A. and Berkovich, L. and Earon, G. and Ron, I. and Lev-Ari, S (2013) 'Escin Chemosensitizes Human Pancreatic Cancer Cells and Inhibits the Nuclear Factor-kappaB Signaling Pathway', Biochemistry Research International, 2013, pp. 251752. doi:10.1155/2013/251752 Preclinical
    https://doi.org/10.1155/2013/251752
  16. Domanski, D., Zegrocka-Stendel, O., Perzanowska, A., Dutkiewicz, M., Kowalewska, M., Grabowska, I., Maciejko, D., Fogtman, A., Dadlez, M. and Koziak, K (2016) 'Molecular Mechanism for Cellular Response to beta-Escin and Its Therapeutic Implications', PLoS One, 11(10). doi:10.1371/journal.pone.0164365 Preclinical
    https://doi.org/10.1371/journal.pone.0164365
  17. Gloviczki, M.L., Kakkos, S.K., Urbanek, T., Chuback, J. and Nicolaides, A (2025) 'The role of venoactive compounds in the treatment of chronic venous disease', Journal of Vascular Surgery: Venous and Lymphatic Disorders, 13(5). doi:10.1016/j.jvsv.2025.102258 Preclinical
    https://doi.org/10.1016/j.jvsv.2025.102258
  18. Santiago, F.R., Grillo, L., Amore, M., Carmelino, C., Trejo, J.M.R. and Ulloa, J.H (2026) 'Venoactive drugs in the management of chronic venous disease: A critical appraisal of the evidence and comparison with international guidelines', Vascular Pharmacology. doi:10.1016/j.vph.2026.107614 Preclinical
    https://doi.org/10.1016/j.vph.2026.107614
  19. Pittler, M.H. and Ernst, E (2006) 'Horse chestnut seed extract for chronic venous insufficiency', Cochrane Database of Systematic Reviews, 2006(1), pp. CD003230. doi:10.1002/14651858.CD003230.pub3 Meta-analysis / review
    https://doi.org/10.1002/14651858.CD003230.pub3
  1. Dong, X., Fu, J., Yin, X., Cao, S. and others (2016) 'Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics', Phytotherapy Research, 30(8), pp. 1207-1218. doi:10.1002/ptr.5631 Traditional / reference
    https://doi.org/10.1002/ptr.5631
  2. Wang, S., Yang, Y., Sun, L., Qiao, G. and others (2022) 'Reynoutria japonica Houtt for Acute Respiratory Tract Infections in Adults and Children: A Systematic Review', Frontiers in Pharmacology, 13, pp. 787032. doi:10.3389/fphar.2022.787032 Meta-analysis / review
    https://doi.org/10.3389/fphar.2022.787032
  3. Ke, Y., Zhan, L., Lu, T., Zhou, C. and others (2023) 'Advances for pharmacological activities of Polygonum cuspidatum (Reynoutria japonica) - A review', Pharmaceutical Biology, 61(1), pp. 177-188. doi:10.1080/13880209.2022.2158349 Traditional / reference
    https://doi.org/10.1080/13880209.2022.2158349
  4. Zhang, Q., Zhao, Y., Zhang, M., Zhang, Y. and others (2021) 'Bioactive amides from Reynoutria japonica', Journal of Asian Natural Products Research, 23(3), pp. 228-234. doi:10.1080/10286020.2021.1873298 Preclinical
    https://doi.org/10.1080/10286020.2021.1873298
  5. Lai, Y., Zhou, C., Huang, P., Dong, Z. and others (2024) 'Polygonum cuspidatum polysaccharide: A review of its extraction and purification, structure analysis, and biological activity', Journal of Ethnopharmacology, 331, pp. 118079. doi:10.1016/j.jep.2024.118079 Traditional / reference
    https://doi.org/10.1016/j.jep.2024.118079
  6. Peng, W., Qin, R., Li, X. and Zhou, H (2013) 'Botany, phytochemistry, pharmacology, and potential application of Polygonum cuspidatum Sieb. et Zucc.: a review', Journal of Ethnopharmacology, 148(3), pp. 729-745. doi:10.1016/j.jep.2013.05.007 Traditional / reference
    https://doi.org/10.1016/j.jep.2013.05.007
  7. Wang, X., Liang, L., Yan, J., Li, Z. and others (2023) 'Citri Reticulatae Pericarpium-Reynoutria japonica Houtt. herb pair suppresses breast cancer liver metastasis by targeting ECM1-mediated cholesterol biosynthesis pathway', Phytomedicine, 116, pp. 154896. doi:10.1016/j.phymed.2023.154896 Preclinical
    https://doi.org/10.1016/j.phymed.2023.154896
  8. Jiang, Y., Liu, Y., Zhang, X. and others (2020) 'New phenolic glycosides from Reynoutria japonica', Journal of Asian Natural Products Research, 22(1), pp. 17-23. doi:10.1080/10286020.2019.1646730 Preclinical
    https://doi.org/10.1080/10286020.2019.1646730
  9. Liu, Y., Wang, J., Li, Q. and others (2024) 'The Possibility of Polygonum cuspidatum against Osteoarthritis based on Network Pharmacology', Current Computer-Aided Drug Design, 20(2), pp. 121-133. doi:10.2174/1573409919666230403114131 Preclinical
    https://doi.org/10.2174/1573409919666230403114131
  10. Espinosa-Andrews, H., Morales-Hernandez, N., Garcia-Marquez, E. and others (2025) 'Physicochemical and rheological characteristics of commercial Greek-style yogurt enriched with Polygonum cuspidatum roots or the P. cuspidatum beta-cyclodextrin inclusion complex', Food Research International, 203, pp. 115854. doi:10.1016/j.foodres.2025.115854 Preclinical
    https://doi.org/10.1016/j.foodres.2025.115854
  11. Burns, J., Yokota, T., Ashihara, H., Lean, M.E.J. and Crozier, A (2002) 'Plant foods and herbal sources of resveratrol', 50(11), pp. 3337--3340. doi:10.1021/jf0112973 Traditional / reference
    https://doi.org/10.1021/jf0112973
  12. Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
    https://powo.science.kew.org
  13. World Health Organization (2007) 'WHO Monographs on Selected Medicinal Plants'. Traditional / reference
    https://scholar.google.com/scholar?q=WHO%20Monographs%20on%20Selected%20Medicinal%20Plants
  14. Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
    https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition

Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.